Baseline covariates of the SMIL cohort in 2018–2022
| Variable | Level | 2018 (n=4079) | 2019 (n=6846) | 2020 (n=9325) | 2021 (n=11 552) | 2022 (n=11 214) |
| Sex, n (%) | Male | 2825 (69.3) | 4619 (67.5) | 5902 (63.3) | 7174 (62.1) | 6998 (62.4) |
| Age of shopper (years), n (%) | <25 | 341 (8.4) | 612 (8.9) | 788 (8.5) | 925 (8.0) | 731 (6.5) |
| (25–35) | 697 (17.1) | 1212 (17.7) | 1586 (17.0) | 1897 (16.4) | 1785 (15.9) | |
| (35–45) | 960 (23.5) | 1565 (22.9) | 2048 (22.0) | 2459 (21.3) | 2329 (20.8) | |
| (45–55) | 1067 (26.2) | 1703 (24.9) | 2341 (25.1) | 2830 (24.5) | 2739 (24.4) | |
| (55–65) | 642 (15.7) | 1087 (15.9) | 1569 (16.8) | 2008 (17.4) | 2075 (18.5) | |
| (65–75) | 334 (8.2) | 583 (8.5) | 853 (9.1) | 1195 (10.3) | 1259 (11.2) | |
| >75 | 38 (0.9) | 84 (1.2) | 140 (1.5) | 238 (2.1) | 296 (2.6) | |
| Educational level, n (%) | Group 1 | 439 (10.8) | 731 (10.7) | 1019 (10.9) | 1381 (12.0) | 1291 (11.5) |
| Group 2 | 1508 (37.0) | 2486 (36.3) | 3383 (36.3) | 4241 (36.7) | 4059 (36.2) | |
| Group 3 | 1274 (31.2) | 2145 (31.3) | 2929 (31.4) | 3554 (30.8) | 3481 (31.0) | |
| Group 4 | 846 (20.7) | 1463 (21.4) | 1962 (21.0) | 2343 (20.3) | 2345 (20.9) | |
| missing | 12 (0.3) | 21 (0.3) | 32 (0.3) | 33 (0.3) | 38 (0.3) | |
| Income (DKK)*, n (%) | <221 000 | 1116 (27.4) | 1853 (27.1) | 2388 (25.6) | 2869 (24.8) | 2502 (22.3) |
| (221 000–298 000) | 1088 (26.7) | 1754 (25.6) | 2386 (25.6) | 2855 (24.7) | 2645 (23.6) | |
| (298.000–387 000) | 992 (24.3) | 1681 (24.6) | 2311 (24.8) | 2915 (25.2) | 2829 (25.2) | |
| >387 000 | 875 (21.5) | 1543 (22.5) | 2214 (23.7) | 2881 (24.9) | 3215 (28.7) | |
| missing | 8 (0.2) | 15 (0.2) | 26 (0.3) | 32 (0.3) | 23 (0.2) | |
| Degree of urbanisation, n (%) | Rural | 998 (24.5) | 1724 (25.2) | 2448 (26.3) | 3152 (27.3) | 3104 (27.7) |
| Suburban | 1308 (32.1) | 2183 (31.9) | 3041 (32.6) | 3846 (33.3) | 3767 (33.6) | |
| Urban | 1773 (43.5) | 2939 (42.9) | 3836 (41.1) | 4554 (39.4) | 4343 (38.7) | |
| Prevalent diseases when entering the calendar year | ||||||
| Atrial fibrillation, n (%) | 79 (1.9) | 127 (1.9) | 163 (1.7) | 214 (1.9) | 210 (1.9) | |
| Cancer, n (%) | 194 (4.8) | 363 (5.3) | 508 (5.4) | 625 (5.4) | 603 (5.4) | |
| Chronic obstructive lung disease, n (%) | 672 (16.5) | 1219 (17.8) | 1749 (18.8) | 2328 (20.2) | 2366 (21.1) | |
| Cardiovascular disease, n (%) | 850 (20.8) | 1447 (21.1) | 1912 (20.5) | 2388 (20.7) | 2318 (20.7) | |
| Depression, n (%) | 49 (1.2) | 90 (1.3) | 116 (1.2) | 149 (1.3) | 146 (1.3) | |
| Diabetes, n (%) | 298 (7.3) | 481 (7.0) | 646 (6.9) | 841 (7.3) | 905 (8.1) | |
| Heart failure, n (%) | 48 (1.2) | 84 (1.2) | 100 (1.1) | 123 (1.1) | 119 (1.1) | |
| Hypertension, n (%) | 491 (12.0) | 811 (11.8) | 1119 (12.0) | 1517 (13.1) | 1553 (13.8) | |
| Ischaemic heart diseases, n (%) | 165 (4.0) | 285 (4.2) | 391 (4.2) | 505 (4.4) | 508 (4.5) | |
| Myocardial infarction, n (%) | 68 (1.7) | 116 (1.7) | 159 (1.7) | 212 (1.8) | 230 (2.1) | |
| Other mental, n (%) | 25 (0.6) | 43 (0.6) | 65 (0.7) | 82 (0.7) | 87 (0.8) | |
| Peripheral vascular disease, n (%) | 62 (1.5) | 106 (1.5) | 124 (1.3) | 160 (1.4) | 156 (1.4) | |
| Renal disease, n (%) | 32 (0.8) | 49 (0.7) | 70 (0.8) | 92 (0.8) | 86 (0.8) | |
| Stroke, n (%) | 95 (2.3) | 164 (2.4) | 218 (2.3) | 278 (2.4) | 266 (2.4) | |
| Unstable angina pectoris, n (%) | 135 (3.3) | 229 (3.3) | 317 (3.4) | 401 (3.5) | 400 (3.6) | |
| Medication prescriptions six months prior to calendar year | ||||||
| Beta blockers, n (%) | 178 (4.4) | 273 (4.0) | 386 (4.1) | 505 (4.4) | 485 (4.3) | |
| Calcium channel blockers, n (%) | 214 (5.2) | 339 (5.0) | 474 (5.1) | 640 (5.5) | 632 (5.6) | |
| Renin-angiotensin-system acting agents, n (%) | 473 (11.6) | 742 (10.8) | 1015 (10.9) | 1344 (11.6) | 1321 (11.8) | |
| Thiazide diuretics, n (%) | 108 (2.6) | 166 (2.4) | 235 (2.5) | 313 (2.7) | 314 (2.8) | |
| Loop diuretics, n (%) | 42 (1.0) | 73 (1.1) | 94 (1.0) | 145 (1.3) | 130 (1.2) | |
| Aldosterone receptor antagonists, n (%) | 30 (0.7) | 40 (0.6) | 59 (0.6) | 91 (0.8) | 84 (0.7) | |
| Digoxin, n (%) | 5 (0.1) | 7 (0.1) | 9 (0.1) | 14 (0.1) | 12 (0.1) | |
| Statins, n (%) | 417 (10.2) | 652 (9.5) | 896 (9.6) | 1183 (10.2) | 1167 (10.4) | |
| Acetylsalicylic acid, n (%) | 230 (5.6) | 356 (5.2) | 467 (5.0) | 560 (4.8) | 542 (4.8) | |
| ADP receptor inhibitor, n (%) | 147 (3.6) | 235 (3.4) | 293 (3.1) | 365 (3.2) | 357 (3.2) | |
| Vitamin K antagonists, n (%) | 184 (4.5) | 301 (4.4) | 399 (4.3) | 504 (4.4) | 495 (4.4) | |
| Direct oral anticoagulant, n (%) | 18 (0.4) | 30 (0.4) | 40 (0.4) | 57 (0.5) | 57 (0.5) | |
| INH C, n (%) | 35 (0.9) | 54 (0.8) | 77 (0.8) | 122 (1.1) | 116 (1.0) | |
| INH B2, n (%) | 159 (3.9) | 247 (3.6) | 344 (3.7) | 449 (3.9) | 441 (3.9) | |
| INH muscular, n (%) | 178 (4.4) | 292 (4.3) | 425 (4.6) | 566 (4.9) | 548 (4.9) | |
| Antidepressants, n (%) | 21 (0.5) | 32 (0.5) | 47 (0.5) | 63 (0.5) | 58 (0.5) | |
| Anti-psychotics, n (%) | 253 (6.2) | 448 (6.5) | 636 (6.8) | 840 (7.3) | 819 (7.3) | |
| Purchasing characteristics | ||||||
| DKK spent per year, median (IQR)* | 8218 (859–4631) | 7032 (2785–13 816) | 6326 (1940–14 729) | 7673 (2667–16 750) | 7671 (2753–15 341) | |
| Number of shopping trips per year, median (IQR) | 15 (6–27) | 49 (21–90) | 45 (15–95) | 55 (22–111) | 63 (26–116) | |
*June 2023: DKK100 approximates €13.42.
INH, isoniazid; SMIL, Health, Food, Purchases and Lifestyle.